| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polymorphism, Single Nucleotide | 290 | 2021 | 2399 | 14.770 |
Why?
|
| Genetic Predisposition to Disease | 176 | 2021 | 2322 | 8.680 |
Why?
|
| Genome-Wide Association Study | 152 | 2022 | 1662 | 7.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 114 | 2020 | 1256 | 6.400 |
Why?
|
| Cancer Vaccines | 32 | 2022 | 160 | 5.790 |
Why?
|
| Lung Neoplasms | 76 | 2020 | 2332 | 5.790 |
Why?
|
| Histone-Lysine N-Methyltransferase | 29 | 2023 | 159 | 5.180 |
Why?
|
| Gene Expression Profiling | 95 | 2018 | 1424 | 5.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 105 | 2016 | 697 | 5.040 |
Why?
|
| Neoplasms | 62 | 2024 | 2998 | 4.980 |
Why?
|
| Breast Neoplasms | 70 | 2022 | 2974 | 4.910 |
Why?
|
| Humans | 805 | 2024 | 88403 | 4.700 |
Why?
|
| Japan | 130 | 2021 | 303 | 4.630 |
Why?
|
| Antigens, Neoplasm | 29 | 2024 | 330 | 4.610 |
Why?
|
| Cell Line, Tumor | 164 | 2024 | 2531 | 4.500 |
Why?
|
| Immunotherapy | 24 | 2021 | 656 | 4.070 |
Why?
|
| Biomarkers, Tumor | 62 | 2022 | 1519 | 3.620 |
Why?
|
| Nuclear Proteins | 35 | 2017 | 727 | 3.620 |
Why?
|
| Pharmacogenetics | 24 | 2024 | 441 | 3.440 |
Why?
|
| Case-Control Studies | 138 | 2021 | 1848 | 3.380 |
Why?
|
| Cell Proliferation | 64 | 2020 | 1640 | 3.370 |
Why?
|
| Receptors, Antigen, T-Cell | 18 | 2024 | 384 | 3.320 |
Why?
|
| Genotype | 120 | 2021 | 1867 | 3.270 |
Why?
|
| Genome, Human | 48 | 2014 | 766 | 3.220 |
Why?
|
| Female | 379 | 2024 | 45647 | 3.160 |
Why?
|
| Cytochrome P-450 CYP2D6 | 17 | 2016 | 52 | 3.070 |
Why?
|
| Neoplasm Proteins | 30 | 2018 | 539 | 3.050 |
Why?
|
| Tumor Suppressor Protein p53 | 28 | 2020 | 408 | 3.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 10 | 2024 | 126 | 3.040 |
Why?
|
| Middle Aged | 276 | 2024 | 25625 | 2.980 |
Why?
|
| Stomach Neoplasms | 21 | 2020 | 269 | 2.980 |
Why?
|
| Aged | 228 | 2024 | 18887 | 2.940 |
Why?
|
| Precision Medicine | 12 | 2021 | 407 | 2.910 |
Why?
|
| Cell Cycle Proteins | 26 | 2017 | 399 | 2.910 |
Why?
|
| Antineoplastic Agents | 44 | 2021 | 2404 | 2.870 |
Why?
|
| Tamoxifen | 18 | 2019 | 168 | 2.860 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 84 | 2013 | 891 | 2.850 |
Why?
|
| Colorectal Neoplasms | 35 | 2024 | 966 | 2.750 |
Why?
|
| Genetic Loci | 35 | 2021 | 253 | 2.710 |
Why?
|
| Male | 330 | 2024 | 41917 | 2.690 |
Why?
|
| Tumor Microenvironment | 10 | 2024 | 448 | 2.670 |
Why?
|
| Linkage Disequilibrium | 76 | 2019 | 474 | 2.640 |
Why?
|
| Peptides | 25 | 2023 | 646 | 2.600 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2019 | 603 | 2.590 |
Why?
|
| DNA-Binding Proteins | 41 | 2018 | 1238 | 2.560 |
Why?
|
| Transcription Factors | 40 | 2020 | 1642 | 2.560 |
Why?
|
| Genetic Variation | 51 | 2020 | 1368 | 2.560 |
Why?
|
| Esophageal Neoplasms | 19 | 2022 | 329 | 2.520 |
Why?
|
| RNA, Small Interfering | 71 | 2019 | 558 | 2.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 33 | 2018 | 1107 | 2.450 |
Why?
|
| Carrier Proteins | 26 | 2016 | 679 | 2.320 |
Why?
|
| Urinary Bladder Neoplasms | 18 | 2018 | 393 | 2.320 |
Why?
|
| Up-Regulation | 43 | 2020 | 729 | 2.310 |
Why?
|
| Gene Frequency | 70 | 2020 | 684 | 2.240 |
Why?
|
| N-Acetylgalactosaminyltransferases | 7 | 2019 | 12 | 2.230 |
Why?
|
| Pancreatic Neoplasms | 25 | 2022 | 659 | 2.200 |
Why?
|
| Polymorphism, Genetic | 32 | 2017 | 824 | 2.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 12 | 2024 | 583 | 2.170 |
Why?
|
| Adult | 199 | 2022 | 26278 | 2.110 |
Why?
|
| Lymph Nodes | 8 | 2024 | 546 | 2.110 |
Why?
|
| Alleles | 59 | 2018 | 1131 | 2.110 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 9 | 2019 | 102 | 2.090 |
Why?
|
| Head and Neck Neoplasms | 11 | 2023 | 1057 | 2.060 |
Why?
|
| Haplotypes | 53 | 2013 | 637 | 2.020 |
Why?
|
| Membrane Proteins | 19 | 2016 | 1213 | 2.010 |
Why?
|
| Neoplastic Stem Cells | 6 | 2020 | 160 | 1.980 |
Why?
|
| Mutation | 40 | 2022 | 4092 | 1.900 |
Why?
|
| Antineoplastic Agents, Hormonal | 13 | 2019 | 156 | 1.900 |
Why?
|
| Aged, 80 and over | 87 | 2020 | 6706 | 1.880 |
Why?
|
| Cell Transformation, Neoplastic | 19 | 2017 | 447 | 1.860 |
Why?
|
| Carcinoma, Renal Cell | 13 | 2016 | 432 | 1.850 |
Why?
|
| Repressor Proteins | 17 | 2020 | 418 | 1.840 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2019 | 2532 | 1.830 |
Why?
|
| Histones | 17 | 2020 | 326 | 1.820 |
Why?
|
| Carcinoma, Squamous Cell | 21 | 2017 | 1093 | 1.820 |
Why?
|
| GTPase-Activating Proteins | 7 | 2020 | 67 | 1.810 |
Why?
|
| DNA, Complementary | 34 | 2012 | 392 | 1.810 |
Why?
|
| Adenocarcinoma | 27 | 2018 | 1184 | 1.790 |
Why?
|
| Molecular Sequence Data | 68 | 2015 | 3028 | 1.780 |
Why?
|
| T-Lymphocytes, Cytotoxic | 28 | 2022 | 317 | 1.730 |
Why?
|
| Lysine | 13 | 2020 | 149 | 1.720 |
Why?
|
| Kidney Neoplasms | 14 | 2016 | 630 | 1.720 |
Why?
|
| Biological Specimen Banks | 18 | 2021 | 65 | 1.710 |
Why?
|
| Apoptosis | 42 | 2020 | 1715 | 1.660 |
Why?
|
| Ubiquitin-Protein Ligases | 18 | 2024 | 170 | 1.640 |
Why?
|
| Methylation | 25 | 2018 | 265 | 1.630 |
Why?
|
| Genomics | 8 | 2021 | 740 | 1.630 |
Why?
|
| Sequence Analysis, DNA | 27 | 2020 | 863 | 1.620 |
Why?
|
| Signal Transduction | 41 | 2018 | 3361 | 1.620 |
Why?
|
| Circulating Tumor DNA | 6 | 2022 | 47 | 1.610 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 18 | 2016 | 385 | 1.610 |
Why?
|
| Chromosome Mapping | 37 | 2019 | 1077 | 1.570 |
Why?
|
| Naphthyridines | 6 | 2019 | 27 | 1.550 |
Why?
|
| Proteins | 19 | 2013 | 786 | 1.540 |
Why?
|
| Carcinoma, Hepatocellular | 19 | 2018 | 404 | 1.520 |
Why?
|
| Proto-Oncogene Proteins c-akt | 12 | 2016 | 340 | 1.510 |
Why?
|
| Liver Neoplasms | 23 | 2018 | 768 | 1.510 |
Why?
|
| Prognosis | 62 | 2020 | 3747 | 1.490 |
Why?
|
| DNA | 19 | 2013 | 1308 | 1.490 |
Why?
|
| Dendritic Cells | 9 | 2023 | 436 | 1.480 |
Why?
|
| Epitopes, T-Lymphocyte | 9 | 2022 | 88 | 1.480 |
Why?
|
| T-Lymphocytes | 12 | 2021 | 1216 | 1.450 |
Why?
|
| Ovarian Neoplasms | 8 | 2020 | 759 | 1.440 |
Why?
|
| Receptors, Cell Surface | 8 | 2014 | 289 | 1.440 |
Why?
|
| Hepatitis C, Chronic | 17 | 2013 | 127 | 1.420 |
Why?
|
| Transfection | 44 | 2016 | 912 | 1.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2017 | 1163 | 1.400 |
Why?
|
| Animals | 149 | 2023 | 27155 | 1.380 |
Why?
|
| High-Throughput Nucleotide Sequencing | 13 | 2022 | 477 | 1.360 |
Why?
|
| Protein Processing, Post-Translational | 12 | 2018 | 380 | 1.360 |
Why?
|
| Mice | 104 | 2023 | 11690 | 1.360 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 2018 | 100 | 1.350 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2015 | 782 | 1.340 |
Why?
|
| Tumor Cells, Cultured | 38 | 2020 | 1056 | 1.330 |
Why?
|
| Vaccines, Subunit | 13 | 2018 | 55 | 1.320 |
Why?
|
| Interleukins | 15 | 2013 | 135 | 1.320 |
Why?
|
| Sarcoma, Synovial | 9 | 2021 | 21 | 1.290 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2015 | 307 | 1.290 |
Why?
|
| Arthritis, Rheumatoid | 18 | 2013 | 167 | 1.290 |
Why?
|
| Base Sequence | 52 | 2020 | 2331 | 1.290 |
Why?
|
| Molecular Targeted Therapy | 8 | 2017 | 283 | 1.280 |
Why?
|
| Epitopes | 17 | 2023 | 255 | 1.270 |
Why?
|
| Colonic Neoplasms | 16 | 2017 | 565 | 1.260 |
Why?
|
| Gene Knockdown Techniques | 16 | 2019 | 245 | 1.260 |
Why?
|
| Trans-Activators | 15 | 2014 | 443 | 1.250 |
Why?
|
| Amino Acid Sequence | 42 | 2016 | 2061 | 1.240 |
Why?
|
| ErbB Receptors | 8 | 2019 | 496 | 1.230 |
Why?
|
| Carcinoma, Pancreatic Ductal | 9 | 2011 | 112 | 1.230 |
Why?
|
| Receptors, G-Protein-Coupled | 12 | 2009 | 126 | 1.210 |
Why?
|
| Prostatic Neoplasms | 21 | 2024 | 1763 | 1.200 |
Why?
|
| COS Cells | 35 | 2016 | 167 | 1.200 |
Why?
|
| Transcription, Genetic | 25 | 2017 | 1155 | 1.170 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2020 | 294 | 1.130 |
Why?
|
| Immunohistochemistry | 49 | 2020 | 1788 | 1.120 |
Why?
|
| Tumor Suppressor Proteins | 17 | 2012 | 289 | 1.120 |
Why?
|
| Warfarin | 5 | 2013 | 104 | 1.100 |
Why?
|
| Promoter Regions, Genetic | 37 | 2019 | 956 | 1.090 |
Why?
|
| HLA-A Antigens | 11 | 2022 | 40 | 1.090 |
Why?
|
| Blotting, Western | 29 | 2015 | 797 | 1.080 |
Why?
|
| Diabetic Nephropathies | 7 | 2011 | 87 | 1.070 |
Why?
|
| Immunoglobulin Isotypes | 2 | 2018 | 31 | 1.060 |
Why?
|
| Genetic Association Studies | 13 | 2021 | 294 | 1.060 |
Why?
|
| Phosphorylation | 27 | 2017 | 1128 | 1.050 |
Why?
|
| Asthma | 19 | 2016 | 973 | 1.050 |
Why?
|
| RNA, Messenger | 50 | 2018 | 2005 | 1.040 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 6 | 2018 | 27 | 1.040 |
Why?
|
| Chromosomal Proteins, Non-Histone | 5 | 2015 | 59 | 1.040 |
Why?
|
| ATP-Binding Cassette Transporters | 8 | 2010 | 142 | 1.020 |
Why?
|
| Intracranial Aneurysm | 5 | 2016 | 164 | 1.020 |
Why?
|
| Antiviral Agents | 17 | 2012 | 514 | 1.010 |
Why?
|
| Exome | 2 | 2016 | 127 | 1.010 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 6 | 2013 | 44 | 1.000 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2020 | 611 | 1.000 |
Why?
|
| Polymerase Chain Reaction | 22 | 2011 | 927 | 0.990 |
Why?
|
| Histocompatibility Antigens Class I | 6 | 2020 | 200 | 0.990 |
Why?
|
| Leukopenia | 5 | 2016 | 66 | 0.990 |
Why?
|
| Blotting, Northern | 25 | 2012 | 259 | 0.990 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2012 | 41 | 0.990 |
Why?
|
| Immunotherapy, Active | 2 | 2022 | 15 | 0.980 |
Why?
|
| Interferon-alpha | 11 | 2012 | 235 | 0.980 |
Why?
|
| Chromosomes, Human, Pair 1 | 13 | 2014 | 100 | 0.960 |
Why?
|
| Treatment Outcome | 43 | 2021 | 8139 | 0.960 |
Why?
|
| RNA Interference | 25 | 2017 | 377 | 0.960 |
Why?
|
| Glomerulonephritis, IGA | 5 | 2006 | 10 | 0.960 |
Why?
|
| Protein Binding | 32 | 2017 | 1482 | 0.960 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2015 | 89 | 0.950 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2017 | 102 | 0.950 |
Why?
|
| DNA Methylation | 11 | 2020 | 655 | 0.940 |
Why?
|
| Chromosomes, Human, Pair 6 | 9 | 2012 | 125 | 0.940 |
Why?
|
| Anti-HIV Agents | 3 | 2011 | 154 | 0.940 |
Why?
|
| Protein Methyltransferases | 5 | 2018 | 15 | 0.940 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 409 | 0.930 |
Why?
|
| Down-Regulation | 22 | 2019 | 518 | 0.930 |
Why?
|
| Gene Expression Regulation | 27 | 2021 | 1974 | 0.920 |
Why?
|
| Ribavirin | 15 | 2012 | 58 | 0.920 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2020 | 884 | 0.920 |
Why?
|
| Quinazolines | 7 | 2016 | 221 | 0.920 |
Why?
|
| Estrogen Receptor alpha | 5 | 2020 | 147 | 0.910 |
Why?
|
| Crohn Disease | 11 | 2016 | 747 | 0.910 |
Why?
|
| HEK293 Cells | 19 | 2020 | 635 | 0.900 |
Why?
|
| Chromosomes, Human, Pair 9 | 8 | 2018 | 86 | 0.890 |
Why?
|
| Cell Nucleus | 7 | 2018 | 594 | 0.890 |
Why?
|
| NIH 3T3 Cells | 21 | 2020 | 108 | 0.890 |
Why?
|
| Chromosomes, Human, Pair 5 | 13 | 2014 | 109 | 0.890 |
Why?
|
| Vaccination | 8 | 2020 | 269 | 0.890 |
Why?
|
| Neoplasm Staging | 17 | 2022 | 1978 | 0.880 |
Why?
|
| Obesity | 9 | 2012 | 968 | 0.880 |
Why?
|
| Protein-Arginine N-Methyltransferases | 5 | 2015 | 12 | 0.880 |
Why?
|
| DNA Damage | 16 | 2017 | 371 | 0.880 |
Why?
|
| Receptors, Estrogen | 11 | 2020 | 386 | 0.870 |
Why?
|
| Xenograft Model Antitumor Assays | 13 | 2021 | 470 | 0.870 |
Why?
|
| Introns | 21 | 2012 | 298 | 0.860 |
Why?
|
| Amino Acid Substitution | 18 | 2019 | 338 | 0.860 |
Why?
|
| Lupus Erythematosus, Systemic | 9 | 2013 | 210 | 0.860 |
Why?
|
| Frizzled Receptors | 7 | 2021 | 15 | 0.840 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 5 | 2013 | 13 | 0.840 |
Why?
|
| Cell Adhesion Molecules | 5 | 2009 | 166 | 0.830 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 2021 | 114 | 0.830 |
Why?
|
| Glycoproteins | 7 | 2011 | 235 | 0.830 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2016 | 478 | 0.820 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2024 | 186 | 0.810 |
Why?
|
| Genotyping Techniques | 5 | 2016 | 69 | 0.810 |
Why?
|
| Cell Cycle | 21 | 2016 | 508 | 0.800 |
Why?
|
| Hepacivirus | 15 | 2013 | 165 | 0.800 |
Why?
|
| Thiophenes | 3 | 2019 | 43 | 0.780 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 6 | 2021 | 42 | 0.780 |
Why?
|
| Proto-Oncogene Proteins | 14 | 2012 | 661 | 0.780 |
Why?
|
| Genetic Therapy | 5 | 2021 | 357 | 0.780 |
Why?
|
| Cholangiocarcinoma | 7 | 2024 | 76 | 0.770 |
Why?
|
| Bronchi | 5 | 2017 | 229 | 0.770 |
Why?
|
| Quinolones | 3 | 2019 | 60 | 0.770 |
Why?
|
| Risk Factors | 48 | 2024 | 5434 | 0.760 |
Why?
|
| Esophagectomy | 1 | 2022 | 91 | 0.760 |
Why?
|
| Bile Duct Neoplasms | 7 | 2024 | 89 | 0.760 |
Why?
|
| Cytoskeletal Proteins | 11 | 2011 | 226 | 0.760 |
Why?
|
| Liquid Biopsy | 5 | 2021 | 33 | 0.760 |
Why?
|
| Gene Expression | 28 | 2017 | 1310 | 0.750 |
Why?
|
| Taxoids | 3 | 2016 | 130 | 0.750 |
Why?
|
| Cell Movement | 12 | 2024 | 783 | 0.750 |
Why?
|
| Sentinel Lymph Node | 1 | 2020 | 16 | 0.740 |
Why?
|
| Cell Line | 38 | 2013 | 2498 | 0.740 |
Why?
|
| DNA, Neoplasm | 10 | 2016 | 269 | 0.740 |
Why?
|
| Nevirapine | 2 | 2011 | 5 | 0.740 |
Why?
|
| Immunogenetics | 2 | 2021 | 7 | 0.730 |
Why?
|
| Plasma | 1 | 2020 | 51 | 0.730 |
Why?
|
| Serum | 1 | 2020 | 25 | 0.730 |
Why?
|
| Peptide Fragments | 13 | 2018 | 460 | 0.720 |
Why?
|
| Ascites | 1 | 2020 | 58 | 0.720 |
Why?
|
| Cell Division | 12 | 2011 | 696 | 0.720 |
Why?
|
| Fibroblasts | 8 | 2016 | 754 | 0.720 |
Why?
|
| Quantitative Trait Loci | 12 | 2021 | 606 | 0.720 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2018 | 863 | 0.710 |
Why?
|
| Immunoprecipitation | 18 | 2015 | 139 | 0.710 |
Why?
|
| Databases, Genetic | 9 | 2021 | 263 | 0.710 |
Why?
|
| Life Style | 6 | 2017 | 172 | 0.710 |
Why?
|
| HeLa Cells | 16 | 2016 | 505 | 0.710 |
Why?
|
| DNA Repair | 6 | 2014 | 359 | 0.700 |
Why?
|
| DNA Primers | 24 | 2012 | 543 | 0.700 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2024 | 437 | 0.690 |
Why?
|
| HSP90 Heat-Shock Proteins | 3 | 2018 | 46 | 0.690 |
Why?
|
| Inventions | 1 | 2019 | 13 | 0.680 |
Why?
|
| Preoperative Care | 1 | 2022 | 398 | 0.680 |
Why?
|
| Testis | 8 | 2014 | 152 | 0.680 |
Why?
|
| Transcriptional Activation | 20 | 2016 | 289 | 0.680 |
Why?
|
| Pneumonectomy | 2 | 2013 | 203 | 0.670 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2017 | 131 | 0.670 |
Why?
|
| Myocardial Infarction | 9 | 2014 | 373 | 0.670 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 21 | 0.670 |
Why?
|
| Cluster Analysis | 15 | 2014 | 371 | 0.660 |
Why?
|
| Disease-Free Survival | 12 | 2022 | 1212 | 0.660 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2019 | 1348 | 0.660 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2010 | 201 | 0.660 |
Why?
|
| Carcinoma | 9 | 2021 | 441 | 0.660 |
Why?
|
| Odds Ratio | 23 | 2018 | 685 | 0.660 |
Why?
|
| Oxidoreductases, N-Demethylating | 3 | 2018 | 14 | 0.650 |
Why?
|
| Genetic Markers | 19 | 2013 | 478 | 0.650 |
Why?
|
| Cytochrome P-450 Enzyme System | 4 | 2016 | 79 | 0.650 |
Why?
|
| Phosphoproteins | 5 | 2011 | 260 | 0.650 |
Why?
|
| HLA-A24 Antigen | 14 | 2018 | 19 | 0.640 |
Why?
|
| Collagen | 5 | 2011 | 293 | 0.640 |
Why?
|
| Immunogenetic Phenomena | 1 | 2018 | 5 | 0.640 |
Why?
|
| Reproducibility of Results | 23 | 2016 | 2743 | 0.640 |
Why?
|
| Cadherins | 5 | 2016 | 161 | 0.630 |
Why?
|
| Chromosomes, Human, Pair 8 | 7 | 2013 | 85 | 0.630 |
Why?
|
| Radioimmunotherapy | 6 | 2021 | 27 | 0.630 |
Why?
|
| Algorithms | 11 | 2019 | 1860 | 0.620 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 64 | 0.620 |
Why?
|
| Carcinoma, Small Cell | 5 | 2010 | 133 | 0.620 |
Why?
|
| Antibodies, Monoclonal | 9 | 2018 | 1401 | 0.620 |
Why?
|
| Interferons | 14 | 2012 | 134 | 0.610 |
Why?
|
| Genes, p53 | 9 | 2008 | 109 | 0.610 |
Why?
|
| Calcium-Binding Proteins | 3 | 2016 | 121 | 0.610 |
Why?
|
| E2F1 Transcription Factor | 5 | 2014 | 13 | 0.610 |
Why?
|
| Blood Proteins | 4 | 2012 | 145 | 0.610 |
Why?
|
| Peanut Hypersensitivity | 1 | 2017 | 15 | 0.600 |
Why?
|
| Fibronectins | 4 | 2016 | 102 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 10 | 6 | 2013 | 47 | 0.600 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2016 | 166 | 0.600 |
Why?
|
| Glycosylation | 10 | 2019 | 129 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 12 | 7 | 2021 | 65 | 0.600 |
Why?
|
| Pharmacogenomic Variants | 1 | 2017 | 42 | 0.600 |
Why?
|
| Neutropenia | 3 | 2013 | 216 | 0.600 |
Why?
|
| Chromosomes, Human, Pair 14 | 3 | 2012 | 49 | 0.600 |
Why?
|
| Lymphatic Metastasis | 13 | 2022 | 498 | 0.590 |
Why?
|
| Glucuronosyltransferase | 3 | 2012 | 185 | 0.590 |
Why?
|
| Neoplasm Invasiveness | 7 | 2024 | 573 | 0.590 |
Why?
|
| Postmenopause | 6 | 2017 | 99 | 0.590 |
Why?
|
| Hydrolases | 5 | 2012 | 30 | 0.580 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2010 | 110 | 0.580 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 3 | 2012 | 24 | 0.580 |
Why?
|
| Oncogene Proteins | 5 | 2018 | 61 | 0.570 |
Why?
|
| Homeodomain Proteins | 9 | 2018 | 553 | 0.570 |
Why?
|
| Nitriles | 5 | 2014 | 160 | 0.570 |
Why?
|
| Triazoles | 5 | 2014 | 100 | 0.570 |
Why?
|
| HLA-B Antigens | 4 | 2020 | 27 | 0.570 |
Why?
|
| DNA Copy Number Variations | 6 | 2020 | 176 | 0.560 |
Why?
|
| Genetics, Population | 18 | 2013 | 404 | 0.560 |
Why?
|
| Duodenal Ulcer | 2 | 2013 | 11 | 0.560 |
Why?
|
| Mannosyltransferases | 1 | 2016 | 6 | 0.560 |
Why?
|
| Polymyositis | 1 | 2016 | 6 | 0.560 |
Why?
|
| Amyotrophic Lateral Sclerosis | 6 | 2018 | 187 | 0.560 |
Why?
|
| Enzyme Activation | 12 | 2016 | 698 | 0.560 |
Why?
|
| Young Adult | 34 | 2020 | 6188 | 0.550 |
Why?
|
| Cytokinesis | 2 | 2014 | 57 | 0.550 |
Why?
|
| Interferon Type I | 5 | 2023 | 176 | 0.550 |
Why?
|
| Pulmonary Veins | 1 | 2017 | 88 | 0.540 |
Why?
|
| Phenotype | 22 | 2021 | 2431 | 0.540 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 8 | 2010 | 182 | 0.540 |
Why?
|
| Hepatitis C | 8 | 2013 | 219 | 0.540 |
Why?
|
| Imidazoles | 2 | 2015 | 151 | 0.540 |
Why?
|
| DNA Mutational Analysis | 12 | 2018 | 531 | 0.540 |
Why?
|
| Anticoagulants | 3 | 2013 | 423 | 0.540 |
Why?
|
| RNA-Binding Proteins | 9 | 2018 | 258 | 0.530 |
Why?
|
| Cell Growth Processes | 13 | 2012 | 85 | 0.530 |
Why?
|
| Acyltransferases | 2 | 2013 | 41 | 0.530 |
Why?
|
| Trachea | 1 | 2017 | 291 | 0.530 |
Why?
|
| Disease Progression | 18 | 2016 | 1489 | 0.530 |
Why?
|
| Myasthenia Gravis | 1 | 2016 | 83 | 0.530 |
Why?
|
| Deoxycytidine | 7 | 2018 | 238 | 0.530 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2012 | 699 | 0.520 |
Why?
|
| Anemia | 5 | 2023 | 126 | 0.520 |
Why?
|
| Gene Dosage | 6 | 2014 | 208 | 0.520 |
Why?
|
| Gene Expression Regulation, Enzymologic | 7 | 2016 | 217 | 0.520 |
Why?
|
| Cohort Studies | 26 | 2020 | 2832 | 0.520 |
Why?
|
| Receptor, Endothelin A | 2 | 2012 | 21 | 0.510 |
Why?
|
| Mesothelioma | 2 | 2016 | 321 | 0.510 |
Why?
|
| Unrelated Donors | 1 | 2015 | 44 | 0.510 |
Why?
|
| Nasopharyngeal Neoplasms | 5 | 2016 | 47 | 0.500 |
Why?
|
| Pyrophosphatases | 6 | 2011 | 16 | 0.500 |
Why?
|
| Multidrug Resistance-Associated Proteins | 3 | 2011 | 27 | 0.500 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2015 | 131 | 0.500 |
Why?
|
| Smoking | 8 | 2017 | 617 | 0.500 |
Why?
|
| L-Selectin | 3 | 2006 | 16 | 0.500 |
Why?
|
| Endometrial Neoplasms | 2 | 2017 | 204 | 0.500 |
Why?
|
| Viral Core Proteins | 8 | 2012 | 28 | 0.500 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2014 | 50 | 0.500 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2012 | 379 | 0.500 |
Why?
|
| Aminopyridines | 1 | 2015 | 40 | 0.490 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2014 | 6 | 0.490 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 6 | 2015 | 80 | 0.490 |
Why?
|
| HIV Infections | 4 | 2011 | 827 | 0.490 |
Why?
|
| Helicobacter Infections | 2 | 2018 | 36 | 0.480 |
Why?
|
| Genetic Testing | 11 | 2021 | 536 | 0.480 |
Why?
|
| Keloid | 2 | 2011 | 8 | 0.480 |
Why?
|
| Anthracenes | 2 | 2013 | 16 | 0.480 |
Why?
|
| Exons | 16 | 2012 | 452 | 0.470 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2014 | 33 | 0.470 |
Why?
|
| Risk | 11 | 2014 | 660 | 0.470 |
Why?
|
| Graft vs Host Disease | 4 | 2020 | 358 | 0.470 |
Why?
|
| Adenoma | 3 | 2013 | 242 | 0.470 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2013 | 8 | 0.470 |
Why?
|
| Gene Library | 4 | 2003 | 133 | 0.470 |
Why?
|
| Polyethylene Glycols | 8 | 2012 | 365 | 0.470 |
Why?
|
| Adaptor Proteins, Signal Transducing | 8 | 2015 | 310 | 0.460 |
Why?
|
| Patient Selection | 2 | 2016 | 689 | 0.460 |
Why?
|
| Sulfonamides | 2 | 2013 | 318 | 0.460 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2020 | 115 | 0.450 |
Why?
|
| Leukocytes | 6 | 2014 | 203 | 0.450 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2012 | 110 | 0.450 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 359 | 0.450 |
Why?
|
| Chromosomes, Human, Pair 13 | 9 | 2013 | 51 | 0.450 |
Why?
|
| Thailand | 8 | 2012 | 57 | 0.450 |
Why?
|
| Helicobacter pylori | 1 | 2013 | 36 | 0.440 |
Why?
|
| Phenanthrolines | 1 | 2013 | 7 | 0.440 |
Why?
|
| E-Selectin | 3 | 2006 | 30 | 0.440 |
Why?
|
| Immunoenzyme Techniques | 13 | 2012 | 306 | 0.440 |
Why?
|
| Zinc Fingers | 5 | 2013 | 57 | 0.440 |
Why?
|
| Coordination Complexes | 1 | 2013 | 20 | 0.440 |
Why?
|
| Edetic Acid | 1 | 2013 | 42 | 0.440 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2019 | 1944 | 0.440 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2012 | 8 | 0.440 |
Why?
|
| Aromatase Inhibitors | 5 | 2014 | 29 | 0.430 |
Why?
|
| Tissue Distribution | 11 | 2023 | 292 | 0.430 |
Why?
|
| Alopecia | 1 | 2013 | 34 | 0.430 |
Why?
|
| Germ-Line Mutation | 7 | 2021 | 341 | 0.430 |
Why?
|
| Chromosomes, Mammalian | 1 | 2013 | 36 | 0.430 |
Why?
|
| Binding Sites | 19 | 2016 | 1112 | 0.430 |
Why?
|
| Interleukin-2 | 2 | 2011 | 250 | 0.430 |
Why?
|
| Tenascin | 3 | 2007 | 10 | 0.430 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2013 | 115 | 0.430 |
Why?
|
| Cytoplasm | 5 | 2017 | 284 | 0.430 |
Why?
|
| Vestibule, Labyrinth | 2 | 2003 | 44 | 0.430 |
Why?
|
| Platinum | 1 | 2013 | 63 | 0.430 |
Why?
|
| Models, Genetic | 13 | 2016 | 942 | 0.430 |
Why?
|
| Sulfotransferases | 4 | 2016 | 19 | 0.430 |
Why?
|
| Doxorubicin | 8 | 2015 | 298 | 0.430 |
Why?
|
| Serum Albumin | 2 | 2012 | 128 | 0.430 |
Why?
|
| Follow-Up Studies | 13 | 2022 | 3652 | 0.420 |
Why?
|
| Mixed Function Oxygenases | 5 | 2013 | 69 | 0.420 |
Why?
|
| Protein Transport | 9 | 2017 | 419 | 0.420 |
Why?
|
| Annexin A3 | 1 | 2012 | 1 | 0.420 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2012 | 1 | 0.420 |
Why?
|
| Zinc | 1 | 2013 | 93 | 0.420 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2012 | 8 | 0.420 |
Why?
|
| Paralysis, Hyperkalemic Periodic | 1 | 2012 | 1 | 0.420 |
Why?
|
| Mammary Glands, Human | 2 | 2014 | 22 | 0.420 |
Why?
|
| Nuclear Envelope | 1 | 2012 | 38 | 0.420 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 2020 | 164 | 0.410 |
Why?
|
| Forkhead Box Protein M1 | 6 | 2017 | 16 | 0.410 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 2 | 2011 | 5 | 0.410 |
Why?
|
| Camptothecin | 3 | 2009 | 191 | 0.410 |
Why?
|
| HLA-DR Antigens | 5 | 2009 | 59 | 0.410 |
Why?
|
| Antibodies | 3 | 2012 | 354 | 0.410 |
Why?
|
| Gallbladder Neoplasms | 1 | 2012 | 23 | 0.410 |
Why?
|
| Genetics, Medical | 2 | 2010 | 52 | 0.410 |
Why?
|
| Brain Neoplasms | 3 | 2009 | 775 | 0.410 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2012 | 18 | 0.410 |
Why?
|
| Endometriosis | 3 | 2012 | 59 | 0.410 |
Why?
|
| Paclitaxel | 5 | 2015 | 477 | 0.410 |
Why?
|
| Tissue Extracts | 1 | 2011 | 24 | 0.400 |
Why?
|
| Benzoxazines | 1 | 2011 | 5 | 0.400 |
Why?
|
| Dermatitis, Atopic | 4 | 2013 | 55 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 22 | 5 | 2011 | 44 | 0.400 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2011 | 23 | 0.400 |
Why?
|
| Hyperthyroidism | 1 | 2012 | 75 | 0.400 |
Why?
|
| Thyroid Neoplasms | 3 | 2015 | 417 | 0.400 |
Why?
|
| Schizophrenia | 2 | 2013 | 477 | 0.400 |
Why?
|
| Tissue Array Analysis | 13 | 2016 | 127 | 0.400 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2015 | 351 | 0.400 |
Why?
|
| Leukocyte Count | 6 | 2016 | 222 | 0.400 |
Why?
|
| Biomarkers | 9 | 2018 | 1754 | 0.400 |
Why?
|
| Melanoma | 1 | 2016 | 462 | 0.400 |
Why?
|
| Antibiotics, Antineoplastic | 6 | 2015 | 116 | 0.390 |
Why?
|
| Models, Biological | 10 | 2017 | 1764 | 0.390 |
Why?
|
| Prospective Studies | 10 | 2022 | 4265 | 0.390 |
Why?
|
| Recombinant Proteins | 17 | 2014 | 1019 | 0.390 |
Why?
|
| Patient Care | 1 | 2012 | 101 | 0.390 |
Why?
|
| Liver | 10 | 2016 | 1241 | 0.390 |
Why?
|
| Vitamin K Epoxide Reductases | 5 | 2019 | 16 | 0.390 |
Why?
|
| Epithelial Cells | 8 | 2017 | 686 | 0.390 |
Why?
|
| Prostatic Hyperplasia | 1 | 2012 | 91 | 0.390 |
Why?
|
| Drug Eruptions | 1 | 2011 | 34 | 0.390 |
Why?
|
| Cytochrome P-450 CYP2C9 | 5 | 2019 | 20 | 0.390 |
Why?
|
| Lim Kinases | 1 | 2011 | 3 | 0.390 |
Why?
|
| HLA-DP Antigens | 4 | 2011 | 8 | 0.390 |
Why?
|
| Computational Biology | 10 | 2017 | 536 | 0.380 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2011 | 14 | 0.380 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 3 | 2023 | 35 | 0.380 |
Why?
|
| Mitochondrial Proteins | 4 | 2010 | 126 | 0.380 |
Why?
|
| Logistic Models | 11 | 2013 | 1204 | 0.380 |
Why?
|
| beta Catenin | 10 | 2011 | 266 | 0.380 |
Why?
|
| Mice, Inbred BALB C | 18 | 2018 | 1084 | 0.380 |
Why?
|
| Organic Anion Transporters | 2 | 2008 | 26 | 0.380 |
Why?
|
| Carbamazepine | 1 | 2010 | 9 | 0.380 |
Why?
|
| Cell Survival | 16 | 2017 | 980 | 0.380 |
Why?
|
| Sirtuin 1 | 1 | 2011 | 32 | 0.380 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 48 | 0.380 |
Why?
|
| Membrane Transport Proteins | 4 | 2012 | 169 | 0.370 |
Why?
|
| Body Mass Index | 6 | 2012 | 767 | 0.370 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2015 | 277 | 0.370 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 577 | 0.370 |
Why?
|
| RNA, Antisense | 1 | 2010 | 15 | 0.370 |
Why?
|
| Nerve Tissue Proteins | 6 | 2012 | 511 | 0.370 |
Why?
|
| Polyglutamic Acid | 1 | 2010 | 15 | 0.370 |
Why?
|
| Peptide Synthases | 1 | 2010 | 12 | 0.370 |
Why?
|
| Multigene Family | 7 | 2014 | 202 | 0.360 |
Why?
|
| Epigenesis, Genetic | 5 | 2018 | 502 | 0.360 |
Why?
|
| Aspirin | 4 | 2017 | 158 | 0.360 |
Why?
|
| Mice, Nude | 14 | 2018 | 814 | 0.360 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2010 | 25 | 0.360 |
Why?
|
| Adolescent | 30 | 2020 | 9134 | 0.360 |
Why?
|
| Cyclophosphamide | 3 | 2018 | 300 | 0.350 |
Why?
|
| MCF-7 Cells | 6 | 2016 | 113 | 0.350 |
Why?
|
| Organ Specificity | 9 | 2014 | 270 | 0.350 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2010 | 76 | 0.350 |
Why?
|
| Aldehyde Dehydrogenase | 3 | 2009 | 15 | 0.350 |
Why?
|
| Proteinuria | 1 | 2010 | 67 | 0.350 |
Why?
|
| Lectins, C-Type | 5 | 2011 | 86 | 0.350 |
Why?
|
| Child | 24 | 2017 | 7078 | 0.350 |
Why?
|
| Gamma Rays | 5 | 2014 | 73 | 0.350 |
Why?
|
| Anticonvulsants | 1 | 2010 | 125 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 11 | 5 | 2012 | 106 | 0.350 |
Why?
|
| Plagiarism | 1 | 2009 | 8 | 0.350 |
Why?
|
| Scientific Misconduct | 1 | 2009 | 10 | 0.350 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 379 | 0.350 |
Why?
|
| Uterine Neoplasms | 1 | 2013 | 242 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2017 | 562 | 0.350 |
Why?
|
| Alcohol Dehydrogenase | 3 | 2009 | 42 | 0.340 |
Why?
|
| Papillomavirus Infections | 4 | 2023 | 260 | 0.340 |
Why?
|
| Morphogenesis | 1 | 2011 | 206 | 0.340 |
Why?
|
| Receptor, ErbB-2 | 5 | 2020 | 236 | 0.340 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2009 | 3 | 0.340 |
Why?
|
| Predictive Value of Tests | 10 | 2011 | 1704 | 0.340 |
Why?
|
| Receptors, Drug | 3 | 2005 | 54 | 0.340 |
Why?
|
| Receptors, Serotonin | 1 | 2009 | 34 | 0.340 |
Why?
|
| Retinoblastoma Protein | 4 | 2015 | 67 | 0.340 |
Why?
|
| Chlamydophila Infections | 1 | 2009 | 3 | 0.340 |
Why?
|
| Principal Component Analysis | 5 | 2014 | 159 | 0.340 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2009 | 12 | 0.330 |
Why?
|
| Gene Silencing | 10 | 2016 | 178 | 0.330 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2006 | 50 | 0.330 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2009 | 26 | 0.330 |
Why?
|
| Flow Cytometry | 15 | 2014 | 691 | 0.330 |
Why?
|
| Loss of Heterozygosity | 4 | 2014 | 86 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 3 | 8 | 2012 | 54 | 0.330 |
Why?
|
| Testicular Neoplasms | 3 | 2005 | 113 | 0.330 |
Why?
|
| Antigens, CD | 3 | 2019 | 464 | 0.320 |
Why?
|
| Cells, Cultured | 18 | 2018 | 2873 | 0.320 |
Why?
|
| Child, Preschool | 16 | 2017 | 3668 | 0.320 |
Why?
|
| Major Histocompatibility Complex | 5 | 2021 | 82 | 0.320 |
Why?
|
| Structure-Activity Relationship | 5 | 2015 | 411 | 0.320 |
Why?
|
| Time Factors | 16 | 2016 | 5301 | 0.320 |
Why?
|
| Exanthema | 1 | 2009 | 38 | 0.320 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2015 | 87 | 0.320 |
Why?
|
| Proliferating Cell Nuclear Antigen | 3 | 2017 | 67 | 0.320 |
Why?
|
| Histone Demethylases | 3 | 2015 | 32 | 0.320 |
Why?
|
| Bone Marrow Cells | 3 | 2016 | 259 | 0.320 |
Why?
|
| Drug Screening Assays, Antitumor | 6 | 2016 | 78 | 0.320 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2020 | 135 | 0.320 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2008 | 5 | 0.320 |
Why?
|
| Mass Spectrometry | 9 | 2015 | 193 | 0.310 |
Why?
|
| Kidney | 10 | 2016 | 1145 | 0.310 |
Why?
|
| Genes, Tumor Suppressor | 9 | 2015 | 159 | 0.310 |
Why?
|
| HLA-DRB1 Chains | 7 | 2013 | 25 | 0.310 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 223 | 0.310 |
Why?
|
| Proteasome Endopeptidase Complex | 5 | 2013 | 106 | 0.310 |
Why?
|
| Muscular Diseases | 1 | 2008 | 64 | 0.310 |
Why?
|
| Cisplatin | 8 | 2014 | 615 | 0.310 |
Why?
|
| Anticarcinogenic Agents | 2 | 2013 | 73 | 0.310 |
Why?
|
| Cation Transport Proteins | 3 | 2007 | 67 | 0.310 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2015 | 267 | 0.310 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2022 | 14 | 0.310 |
Why?
|
| Simvastatin | 1 | 2008 | 105 | 0.310 |
Why?
|
| Carbon-Carbon Ligases | 1 | 2007 | 2 | 0.310 |
Why?
|
| HCT116 Cells | 9 | 2016 | 155 | 0.310 |
Why?
|
| Adenosine Triphosphatases | 4 | 2024 | 154 | 0.310 |
Why?
|
| Protein-Arginine Deiminases | 6 | 2018 | 6 | 0.310 |
Why?
|
| Cell Membrane Permeability | 4 | 2018 | 120 | 0.300 |
Why?
|
| Peritoneal Neoplasms | 2 | 2020 | 181 | 0.300 |
Why?
|
| Piperazines | 3 | 2007 | 280 | 0.300 |
Why?
|
| Immune Tolerance | 2 | 2009 | 338 | 0.300 |
Why?
|
| Metabolic Syndrome | 1 | 2009 | 129 | 0.300 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2003 | 173 | 0.300 |
Why?
|
| Metalloendopeptidases | 2 | 2004 | 45 | 0.300 |
Why?
|
| Survival Rate | 7 | 2020 | 1881 | 0.300 |
Why?
|
| Toxicogenetics | 1 | 2007 | 1 | 0.300 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2018 | 282 | 0.300 |
Why?
|
| Drug Discovery | 2 | 2021 | 107 | 0.300 |
Why?
|
| Pyrimidines | 4 | 2007 | 372 | 0.300 |
Why?
|
| Abnormalities, Multiple | 1 | 2009 | 234 | 0.300 |
Why?
|
| Seminoma | 2 | 2004 | 13 | 0.300 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2007 | 38 | 0.290 |
Why?
|
| Chromatin | 6 | 2014 | 396 | 0.290 |
Why?
|
| RNA | 7 | 2016 | 575 | 0.290 |
Why?
|
| Protein Isoforms | 7 | 2011 | 272 | 0.290 |
Why?
|
| Osteosarcoma | 2 | 2009 | 160 | 0.290 |
Why?
|
| Blood Coagulation | 1 | 2007 | 92 | 0.290 |
Why?
|
| Leiomyoma | 1 | 2011 | 200 | 0.290 |
Why?
|
| Retrospective Studies | 12 | 2021 | 8859 | 0.290 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2017 | 162 | 0.290 |
Why?
|
| Betacoronavirus | 2 | 2020 | 260 | 0.290 |
Why?
|
| Opisthorchiasis | 1 | 2006 | 1 | 0.290 |
Why?
|
| Neuroblastoma | 2 | 2019 | 394 | 0.280 |
Why?
|
| Tandem Repeat Sequences | 2 | 2009 | 27 | 0.280 |
Why?
|
| Oxidoreductases | 2 | 2015 | 112 | 0.280 |
Why?
|
| Apoptosis Regulatory Proteins | 7 | 2012 | 201 | 0.280 |
Why?
|
| Oligopeptides | 4 | 2012 | 191 | 0.280 |
Why?
|
| Survival Analysis | 11 | 2020 | 1542 | 0.280 |
Why?
|
| Hepatitis B, Chronic | 3 | 2012 | 32 | 0.280 |
Why?
|
| Membrane Glycoproteins | 7 | 2012 | 431 | 0.280 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2021 | 30 | 0.280 |
Why?
|
| Carcinogenesis | 5 | 2020 | 206 | 0.280 |
Why?
|
| Fibroblast Growth Factors | 2 | 2005 | 81 | 0.280 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2009 | 85 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 4 | 5 | 2012 | 48 | 0.280 |
Why?
|
| Radiation Tolerance | 2 | 2009 | 170 | 0.280 |
Why?
|
| Cytokines | 7 | 2018 | 801 | 0.280 |
Why?
|
| HLA-A2 Antigen | 6 | 2014 | 31 | 0.280 |
Why?
|
| Mitochondria | 6 | 2008 | 548 | 0.280 |
Why?
|
| Mice, Knockout | 12 | 2020 | 1986 | 0.280 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 258 | 0.270 |
Why?
|
| Mice, SCID | 6 | 2016 | 261 | 0.270 |
Why?
|
| Cyclins | 2 | 2003 | 83 | 0.270 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 385 | 0.270 |
Why?
|
| Homozygote | 7 | 2012 | 202 | 0.270 |
Why?
|
| Estrogens | 3 | 2020 | 201 | 0.270 |
Why?
|
| Disease | 2 | 2017 | 90 | 0.270 |
Why?
|
| Genes, Reporter | 6 | 2014 | 275 | 0.270 |
Why?
|
| Immunoglobulins | 2 | 2012 | 148 | 0.270 |
Why?
|
| Genome | 4 | 2004 | 376 | 0.270 |
Why?
|
| Brain Ischemia | 3 | 2010 | 402 | 0.270 |
Why?
|
| Genetic Linkage | 9 | 2010 | 624 | 0.270 |
Why?
|
| Neoplasm Metastasis | 8 | 2020 | 1095 | 0.270 |
Why?
|
| Cochlea | 2 | 2003 | 50 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 7 | 4 | 2013 | 79 | 0.270 |
Why?
|
| Cell Differentiation | 8 | 2018 | 1513 | 0.270 |
Why?
|
| Stroke | 3 | 2010 | 978 | 0.270 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 858 | 0.270 |
Why?
|
| Coculture Techniques | 3 | 2022 | 172 | 0.270 |
Why?
|
| Cytochrome P450 Family 4 | 2 | 2019 | 2 | 0.260 |
Why?
|
| Contractile Proteins | 1 | 2005 | 55 | 0.260 |
Why?
|
| Models, Statistical | 6 | 2016 | 575 | 0.260 |
Why?
|
| Genes, MHC Class II | 2 | 2003 | 30 | 0.260 |
Why?
|
| Obesity, Morbid | 1 | 2008 | 230 | 0.260 |
Why?
|
| Protein Interaction Domains and Motifs | 2 | 2017 | 86 | 0.260 |
Why?
|
| Intestinal Neoplasms | 2 | 2008 | 57 | 0.250 |
Why?
|
| KCNQ1 Potassium Channel | 3 | 2010 | 16 | 0.250 |
Why?
|
| Galectin 1 | 1 | 2004 | 6 | 0.250 |
Why?
|
| Osteoarthritis, Knee | 4 | 2010 | 65 | 0.250 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2005 | 55 | 0.250 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 303 | 0.250 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2017 | 119 | 0.250 |
Why?
|
| gamma-Glutamyltransferase | 2 | 2010 | 16 | 0.250 |
Why?
|
| Dinucleoside Phosphates | 1 | 2004 | 9 | 0.250 |
Why?
|
| Cholesterol | 2 | 2017 | 354 | 0.250 |
Why?
|
| RNA Splice Sites | 3 | 2012 | 56 | 0.250 |
Why?
|
| Meta-Analysis as Topic | 6 | 2021 | 86 | 0.250 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 44 | 0.250 |
Why?
|
| Point Mutation | 2 | 2015 | 246 | 0.250 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2004 | 21 | 0.250 |
Why?
|
| Neuropeptides | 3 | 2013 | 113 | 0.250 |
Why?
|
| GTP-Binding Protein alpha Subunits, G12-G13 | 1 | 2004 | 3 | 0.250 |
Why?
|
| Bile Ducts, Intrahepatic | 5 | 2010 | 72 | 0.240 |
Why?
|
| Protein Multimerization | 2 | 2017 | 173 | 0.240 |
Why?
|
| MutL Protein Homolog 1 | 3 | 2021 | 33 | 0.240 |
Why?
|
| Severity of Illness Index | 8 | 2018 | 1841 | 0.240 |
Why?
|
| Pharmacokinetics | 1 | 2004 | 10 | 0.240 |
Why?
|
| Colitis, Ulcerative | 4 | 2013 | 722 | 0.240 |
Why?
|
| Lung | 9 | 2018 | 1241 | 0.240 |
Why?
|
| Receptors, Calcitriol | 2 | 2018 | 129 | 0.240 |
Why?
|
| Chromosome Banding | 1 | 2004 | 74 | 0.240 |
Why?
|
| Bronchodilator Agents | 3 | 2013 | 65 | 0.240 |
Why?
|
| Electrophoretic Mobility Shift Assay | 12 | 2013 | 73 | 0.240 |
Why?
|
| Drug Administration Schedule | 5 | 2016 | 902 | 0.240 |
Why?
|
| Histone Deacetylases | 1 | 2004 | 70 | 0.240 |
Why?
|
| Depressive Disorder, Major | 2 | 2018 | 165 | 0.240 |
Why?
|
| Tumor Burden | 3 | 2021 | 303 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 4 | 2017 | 94 | 0.240 |
Why?
|
| Multiple Myeloma | 2 | 2019 | 326 | 0.230 |
Why?
|
| Medical Oncology | 1 | 2008 | 375 | 0.230 |
Why?
|
| Extracellular Matrix Proteins | 5 | 2009 | 126 | 0.230 |
Why?
|
| Cartilage, Articular | 2 | 2010 | 68 | 0.230 |
Why?
|
| Kruppel-Like Transcription Factors | 3 | 2012 | 98 | 0.230 |
Why?
|
| Yttrium Radioisotopes | 3 | 2021 | 58 | 0.230 |
Why?
|
| Receptors, Steroid | 2 | 2016 | 42 | 0.230 |
Why?
|
| BRCA1 Protein | 2 | 2017 | 202 | 0.230 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 242 | 0.230 |
Why?
|
| Cartilage | 2 | 2003 | 115 | 0.230 |
Why?
|
| Receptors, Polymeric Immunoglobulin | 1 | 2003 | 5 | 0.230 |
Why?
|
| Risk Assessment | 7 | 2017 | 2285 | 0.230 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2003 | 46 | 0.230 |
Why?
|
| Hematinics | 1 | 2023 | 11 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 956 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2016 | 84 | 0.220 |
Why?
|
| Esterases | 1 | 2003 | 13 | 0.220 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2020 | 8 | 0.220 |
Why?
|
| Chelating Agents | 1 | 2023 | 69 | 0.220 |
Why?
|
| Ligases | 1 | 2003 | 45 | 0.220 |
Why?
|
| Proteomics | 5 | 2018 | 227 | 0.220 |
Why?
|
| Rats | 8 | 2015 | 4027 | 0.220 |
Why?
|
| Embryonic Stem Cells | 2 | 2018 | 80 | 0.220 |
Why?
|
| DNA Replication | 5 | 2017 | 169 | 0.220 |
Why?
|
| Ovarian Cysts | 1 | 2003 | 17 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2018 | 237 | 0.220 |
Why?
|
| Transglutaminases | 1 | 2003 | 40 | 0.220 |
Why?
|
| Disease Susceptibility | 7 | 2010 | 199 | 0.220 |
Why?
|
| Ovarian Diseases | 1 | 2003 | 32 | 0.220 |
Why?
|
| CpG Islands | 1 | 2003 | 158 | 0.220 |
Why?
|
| Receptors, Immunologic | 3 | 2009 | 135 | 0.220 |
Why?
|
| Crystallins | 1 | 2002 | 5 | 0.220 |
Why?
|
| Hearing Loss | 1 | 2003 | 59 | 0.220 |
Why?
|
| Remission Induction | 4 | 2021 | 734 | 0.220 |
Why?
|
| Bulgaria | 3 | 2013 | 3 | 0.220 |
Why?
|
| Erythropoietin | 1 | 2023 | 89 | 0.220 |
Why?
|
| Substrate Specificity | 3 | 2018 | 351 | 0.220 |
Why?
|
| Deafness | 1 | 2002 | 47 | 0.220 |
Why?
|
| Mitosis | 2 | 2015 | 152 | 0.220 |
Why?
|
| Mice, Inbred NOD | 5 | 2016 | 194 | 0.220 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2003 | 40 | 0.220 |
Why?
|
| RNA-Binding Protein EWS | 4 | 2018 | 8 | 0.220 |
Why?
|
| Oxonic Acid | 4 | 2012 | 8 | 0.210 |
Why?
|
| Tegafur | 4 | 2012 | 17 | 0.210 |
Why?
|
| Cell Death | 3 | 2014 | 262 | 0.210 |
Why?
|
| Gene Deletion | 4 | 2007 | 341 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 15 | 5 | 2014 | 66 | 0.210 |
Why?
|
| Sensitivity and Specificity | 8 | 2019 | 2019 | 0.210 |
Why?
|
| Nephrolithiasis | 2 | 2013 | 23 | 0.210 |
Why?
|
| Oligonucleotides, Antisense | 6 | 2005 | 68 | 0.210 |
Why?
|
| Administration, Oral | 4 | 2015 | 684 | 0.210 |
Why?
|
| Homeostasis | 2 | 2015 | 407 | 0.210 |
Why?
|
| Isoenzymes | 3 | 2013 | 272 | 0.210 |
Why?
|
| Sulindac | 1 | 2002 | 10 | 0.210 |
Why?
|
| Polysaccharides | 3 | 2012 | 90 | 0.210 |
Why?
|
| Arginine | 4 | 2015 | 138 | 0.210 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2012 | 48 | 0.210 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2024 | 274 | 0.210 |
Why?
|
| Estradiol | 3 | 2013 | 251 | 0.210 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 248 | 0.210 |
Why?
|
| Actinium | 1 | 2021 | 1 | 0.210 |
Why?
|
| Drug Combinations | 5 | 2012 | 203 | 0.210 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 50 | 0.210 |
Why?
|
| Cytodiagnosis | 2 | 2019 | 44 | 0.210 |
Why?
|
| Granuloma | 2 | 2019 | 65 | 0.200 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 38 | 0.200 |
Why?
|
| Luciferases | 9 | 2013 | 128 | 0.200 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 3 | 2013 | 8 | 0.200 |
Why?
|
| ROC Curve | 7 | 2014 | 773 | 0.200 |
Why?
|
| Oncogenes | 3 | 2007 | 92 | 0.200 |
Why?
|
| Drug Therapy, Combination | 9 | 2018 | 798 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 11 | 2020 | 3196 | 0.200 |
Why?
|
| BCG Vaccine | 2 | 2020 | 35 | 0.200 |
Why?
|
| Transcription Factor TFIIIA | 2 | 2012 | 2 | 0.200 |
Why?
|
| Knee Joint | 1 | 2003 | 166 | 0.200 |
Why?
|
| Actins | 2 | 2020 | 456 | 0.200 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 18 | 0.200 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 138 | 0.200 |
Why?
|
| Protein Structure, Tertiary | 10 | 2012 | 740 | 0.200 |
Why?
|
| Lymphocytes | 2 | 2022 | 469 | 0.200 |
Why?
|
| Schizosaccharomyces pombe Proteins | 1 | 2002 | 36 | 0.200 |
Why?
|
| Microfilament Proteins | 6 | 2013 | 212 | 0.200 |
Why?
|
| Chromosomal Instability | 2 | 2014 | 19 | 0.200 |
Why?
|
| Osteoporosis | 2 | 2014 | 122 | 0.200 |
Why?
|
| Cloning, Molecular | 7 | 2012 | 647 | 0.200 |
Why?
|
| beta-Defensins | 2 | 2018 | 12 | 0.200 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 6 | 2014 | 75 | 0.200 |
Why?
|
| Real-Time Polymerase Chain Reaction | 7 | 2018 | 282 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 5 | 2015 | 197 | 0.200 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2003 | 280 | 0.200 |
Why?
|
| Mesoderm | 1 | 2002 | 124 | 0.190 |
Why?
|
| Fucose | 2 | 2012 | 13 | 0.190 |
Why?
|
| Fungal Proteins | 1 | 2002 | 141 | 0.190 |
Why?
|
| Sequence Homology, Amino Acid | 5 | 2005 | 417 | 0.190 |
Why?
|
| TCF Transcription Factors | 4 | 2005 | 24 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-ets | 3 | 2013 | 25 | 0.190 |
Why?
|
| RNA, Neoplasm | 4 | 2016 | 88 | 0.190 |
Why?
|
| Stavudine | 2 | 2011 | 4 | 0.190 |
Why?
|
| Osteoarthritis | 3 | 2007 | 73 | 0.190 |
Why?
|
| Calcium Channels | 2 | 2013 | 182 | 0.190 |
Why?
|
| Antigen Presentation | 2 | 2020 | 214 | 0.190 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 2 | 2012 | 9 | 0.190 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 366 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2012 | 111 | 0.190 |
Why?
|
| Dyslipidemias | 2 | 2017 | 108 | 0.190 |
Why?
|
| Histocompatibility Antigens | 2 | 2011 | 38 | 0.190 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 31 | 0.190 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 34 | 0.190 |
Why?
|
| Chromatin Immunoprecipitation | 8 | 2016 | 136 | 0.190 |
Why?
|
| Models, Molecular | 3 | 2015 | 1294 | 0.190 |
Why?
|
| Enzyme Inhibitors | 4 | 2018 | 645 | 0.190 |
Why?
|
| Rectal Neoplasms | 3 | 2019 | 127 | 0.190 |
Why?
|
| CA-125 Antigen | 1 | 2020 | 22 | 0.190 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 178 | 0.190 |
Why?
|
| Cellular Senescence | 3 | 2012 | 103 | 0.180 |
Why?
|
| DNA Fragmentation | 1 | 2020 | 63 | 0.180 |
Why?
|
| Vaginal Neoplasms | 1 | 2020 | 84 | 0.180 |
Why?
|
| Biological Assay | 2 | 2010 | 79 | 0.180 |
Why?
|
| Carcinogens | 1 | 2020 | 110 | 0.180 |
Why?
|
| Mucin-1 | 2 | 2010 | 45 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 6 | 2011 | 321 | 0.180 |
Why?
|
| Biosensing Techniques | 2 | 2020 | 73 | 0.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2016 | 393 | 0.180 |
Why?
|
| CD8 Antigens | 2 | 2017 | 82 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 5 | 2 | 2012 | 12 | 0.180 |
Why?
|
| Blood | 1 | 2020 | 69 | 0.180 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 2 | 2010 | 30 | 0.180 |
Why?
|
| GPI-Linked Proteins | 8 | 2013 | 51 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2017 | 565 | 0.180 |
Why?
|
| Myofibroblasts | 1 | 2020 | 46 | 0.180 |
Why?
|
| Granzymes | 2 | 2017 | 94 | 0.180 |
Why?
|
| Herpesvirus 1, Human | 2 | 2018 | 244 | 0.180 |
Why?
|
| 3' Untranslated Regions | 6 | 2009 | 95 | 0.180 |
Why?
|
| Aging | 2 | 2016 | 708 | 0.180 |
Why?
|
| Breast | 2 | 2019 | 290 | 0.180 |
Why?
|
| 5' Untranslated Regions | 4 | 2012 | 51 | 0.180 |
Why?
|
| Viral Vaccines | 1 | 2020 | 44 | 0.180 |
Why?
|
| Autocrine Communication | 1 | 2019 | 20 | 0.180 |
Why?
|
| Coronavirus | 1 | 2020 | 18 | 0.180 |
Why?
|
| Open Reading Frames | 1 | 2020 | 119 | 0.180 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 2 | 2014 | 5 | 0.180 |
Why?
|
| Th1 Cells | 2 | 2018 | 165 | 0.180 |
Why?
|
| Urinary Bladder | 3 | 2018 | 246 | 0.180 |
Why?
|
| Bone and Bones | 2 | 2013 | 266 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 63 | 0.170 |
Why?
|
| Antigens, Ly | 3 | 2008 | 37 | 0.170 |
Why?
|
| Molecular Structure | 3 | 2015 | 289 | 0.170 |
Why?
|
| Peptides, Cyclic | 2 | 2009 | 44 | 0.170 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 164 | 0.170 |
Why?
|
| Datasets as Topic | 1 | 2019 | 76 | 0.170 |
Why?
|
| NF-kappa B | 6 | 2012 | 464 | 0.170 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2017 | 90 | 0.170 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 2 | 2011 | 20 | 0.170 |
Why?
|
| STAT3 Transcription Factor | 3 | 2015 | 85 | 0.170 |
Why?
|
| Cathepsins | 2 | 2013 | 21 | 0.170 |
Why?
|
| 5' Flanking Region | 5 | 2007 | 16 | 0.170 |
Why?
|
| Protein Kinase C | 2 | 2013 | 268 | 0.170 |
Why?
|
| Protons | 1 | 2020 | 101 | 0.170 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 172 | 0.170 |
Why?
|
| Lung Abscess | 1 | 2019 | 5 | 0.170 |
Why?
|
| HSP70 Heat-Shock Proteins | 3 | 2012 | 114 | 0.170 |
Why?
|
| Sodium | 2 | 2011 | 331 | 0.170 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 55 | 0.170 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2017 | 75 | 0.170 |
Why?
|
| Genetic Vectors | 7 | 2016 | 443 | 0.170 |
Why?
|
| Coumarins | 1 | 2019 | 13 | 0.170 |
Why?
|
| Osteoarthritis, Hip | 3 | 2010 | 22 | 0.170 |
Why?
|
| Stem Cells | 1 | 2002 | 369 | 0.170 |
Why?
|
| Serpins | 2 | 2012 | 31 | 0.170 |
Why?
|
| Protein Interaction Mapping | 3 | 2011 | 82 | 0.170 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2012 | 121 | 0.170 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2015 | 34 | 0.170 |
Why?
|
| Population Groups | 4 | 2012 | 41 | 0.170 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 158 | 0.170 |
Why?
|
| Brain | 4 | 2020 | 2257 | 0.170 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 190 | 0.170 |
Why?
|
| Hemoglobins | 3 | 2023 | 189 | 0.170 |
Why?
|
| Lymphocyte Activation | 5 | 2018 | 742 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2018 | 32 | 0.160 |
Why?
|
| Cytotoxins | 1 | 2018 | 16 | 0.160 |
Why?
|
| Sesquiterpenes | 1 | 2018 | 13 | 0.160 |
Why?
|
| Astatine | 1 | 2018 | 3 | 0.160 |
Why?
|
| Raloxifene Hydrochloride | 3 | 2015 | 10 | 0.160 |
Why?
|
| Genetic Techniques | 2 | 2009 | 73 | 0.160 |
Why?
|
| RNA, Untranslated | 2 | 2010 | 64 | 0.160 |
Why?
|
| Forkhead Transcription Factors | 4 | 2016 | 171 | 0.160 |
Why?
|
| Combined Modality Therapy | 9 | 2018 | 1709 | 0.160 |
Why?
|
| Radioisotopes | 1 | 2018 | 45 | 0.160 |
Why?
|
| Receptors, IgG | 3 | 2013 | 52 | 0.160 |
Why?
|
| Sialoglycoproteins | 2 | 2010 | 31 | 0.160 |
Why?
|
| Macrophages | 2 | 2020 | 572 | 0.160 |
Why?
|
| Autoantigens | 5 | 2013 | 129 | 0.160 |
Why?
|
| Regression Analysis | 3 | 2013 | 594 | 0.160 |
Why?
|
| Software | 5 | 2011 | 661 | 0.160 |
Why?
|
| Microsomes, Liver | 2 | 2015 | 49 | 0.160 |
Why?
|
| Hepatitis B virus | 3 | 2012 | 44 | 0.160 |
Why?
|
| Receptors, Progesterone | 4 | 2020 | 167 | 0.160 |
Why?
|
| Oncolytic Viruses | 1 | 2018 | 23 | 0.160 |
Why?
|
| Europe | 4 | 2013 | 314 | 0.160 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 56 | 0.160 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2018 | 16 | 0.160 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 163 | 0.160 |
Why?
|
| eIF-2 Kinase | 2 | 2015 | 48 | 0.160 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 351 | 0.160 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 266 | 0.150 |
Why?
|
| Lymph Node Excision | 3 | 2014 | 220 | 0.150 |
Why?
|
| Kynurenine | 1 | 2018 | 21 | 0.150 |
Why?
|
| Acetylation | 3 | 2015 | 132 | 0.150 |
Why?
|
| Cardiovascular Diseases | 3 | 2017 | 705 | 0.150 |
Why?
|
| Uric Acid | 3 | 2012 | 136 | 0.150 |
Why?
|
| Mediastinal Cyst | 1 | 2017 | 3 | 0.150 |
Why?
|
| Bronchogenic Cyst | 1 | 2017 | 5 | 0.150 |
Why?
|
| Cyanobacteria | 1 | 2018 | 113 | 0.150 |
Why?
|
| Calmodulin | 2 | 2010 | 50 | 0.150 |
Why?
|
| Nod2 Signaling Adaptor Protein | 2 | 2011 | 13 | 0.150 |
Why?
|
| Artificial Intelligence | 2 | 2019 | 311 | 0.150 |
Why?
|
| Papillomaviridae | 2 | 2017 | 155 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2015 | 71 | 0.150 |
Why?
|
| Fever | 1 | 2018 | 127 | 0.150 |
Why?
|
| Interferon-gamma | 7 | 2018 | 450 | 0.150 |
Why?
|
| Estrone | 1 | 2017 | 10 | 0.150 |
Why?
|
| Citalopram | 2 | 2014 | 20 | 0.150 |
Why?
|
| United Kingdom | 3 | 2010 | 162 | 0.150 |
Why?
|
| Thy-1 Antigens | 1 | 2017 | 16 | 0.150 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2017 | 22 | 0.150 |
Why?
|
| Early Growth Response Protein 2 | 2 | 2010 | 17 | 0.150 |
Why?
|
| Gene Transfer Techniques | 3 | 2008 | 152 | 0.150 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2010 | 283 | 0.150 |
Why?
|
| CD11c Antigen | 1 | 2017 | 13 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 2 | 3 | 2012 | 85 | 0.150 |
Why?
|
| Artifacts | 2 | 2016 | 244 | 0.150 |
Why?
|
| Ubiquitination | 3 | 2015 | 70 | 0.150 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2017 | 30 | 0.150 |
Why?
|
| Telomere Homeostasis | 1 | 2017 | 30 | 0.150 |
Why?
|
| Endoscopy | 1 | 2020 | 343 | 0.150 |
Why?
|
| Lasers | 4 | 2005 | 107 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 157 | 0.150 |
Why?
|
| Lectins | 3 | 2012 | 84 | 0.150 |
Why?
|
| Pleckstrin Homology Domains | 1 | 2016 | 1 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2631 | 0.140 |
Why?
|
| Chloride Channels | 2 | 2019 | 42 | 0.140 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2017 | 44 | 0.140 |
Why?
|
| Diabetic Neuropathies | 2 | 2007 | 41 | 0.140 |
Why?
|
| Butyrylcholinesterase | 1 | 2016 | 10 | 0.140 |
Why?
|
| Thrombosis | 2 | 2010 | 301 | 0.140 |
Why?
|
| Expressed Sequence Tags | 4 | 2004 | 35 | 0.140 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 31 | 0.140 |
Why?
|
| Caspases | 4 | 2005 | 156 | 0.140 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 45 | 0.140 |
Why?
|
| Serine | 4 | 2011 | 102 | 0.140 |
Why?
|
| RNA Helicases | 2 | 2009 | 35 | 0.140 |
Why?
|
| Epilepsy | 1 | 2021 | 421 | 0.140 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 46 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2011 | 172 | 0.140 |
Why?
|
| Ki-67 Antigen | 1 | 2016 | 66 | 0.140 |
Why?
|
| Azacitidine | 2 | 2014 | 139 | 0.140 |
Why?
|
| Dyneins | 1 | 2016 | 14 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2016 | 25 | 0.140 |
Why?
|
| Histocompatibility Testing | 1 | 2016 | 138 | 0.140 |
Why?
|
| Cystatins | 2 | 2008 | 5 | 0.140 |
Why?
|
| Kinetics | 3 | 2005 | 1528 | 0.140 |
Why?
|
| Organic Cation Transport Proteins | 2 | 2008 | 13 | 0.140 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 93 | 0.140 |
Why?
|
| Netrin Receptors | 2 | 2014 | 7 | 0.140 |
Why?
|
| Interleukin-17 | 3 | 2012 | 105 | 0.140 |
Why?
|
| Proteolysis | 3 | 2012 | 106 | 0.140 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2013 | 31 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 171 | 0.140 |
Why?
|
| Sex Factors | 4 | 2020 | 1062 | 0.140 |
Why?
|
| Prostate-Specific Antigen | 3 | 2017 | 358 | 0.140 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2016 | 5 | 0.140 |
Why?
|
| Stress, Physiological | 2 | 2017 | 231 | 0.140 |
Why?
|
| Cathepsin L | 1 | 2016 | 7 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2012 | 126 | 0.140 |
Why?
|
| A549 Cells | 1 | 2016 | 41 | 0.140 |
Why?
|
| Glycolysis | 1 | 2017 | 133 | 0.140 |
Why?
|
| Subcellular Fractions | 2 | 2007 | 94 | 0.140 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 19 | 0.140 |
Why?
|
| Monitoring, Immunologic | 2 | 2014 | 17 | 0.140 |
Why?
|
| Cystatin C | 1 | 2016 | 28 | 0.140 |
Why?
|
| Plasma Cells | 1 | 2016 | 81 | 0.130 |
Why?
|
| Solubility | 2 | 2015 | 178 | 0.130 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2015 | 12 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 3 | 2012 | 364 | 0.130 |
Why?
|
| Vinblastine | 2 | 2007 | 108 | 0.130 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2015 | 64 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 268 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2017 | 117 | 0.130 |
Why?
|
| U937 Cells | 1 | 2015 | 32 | 0.130 |
Why?
|
| Polyneuropathies | 1 | 2016 | 27 | 0.130 |
Why?
|
| Receptor, EphA4 | 2 | 2006 | 5 | 0.130 |
Why?
|
| Myocarditis | 1 | 2016 | 52 | 0.130 |
Why?
|
| 3T3 Cells | 3 | 2005 | 97 | 0.130 |
Why?
|
| Ipilimumab | 1 | 2016 | 61 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2013 | 80 | 0.130 |
Why?
|
| Shoulder | 1 | 2016 | 42 | 0.130 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2005 | 20 | 0.130 |
Why?
|
| Urothelium | 1 | 2016 | 71 | 0.130 |
Why?
|
| Cause of Death | 4 | 2017 | 270 | 0.130 |
Why?
|
| Heat-Shock Proteins | 1 | 2017 | 181 | 0.130 |
Why?
|
| Ribonucleotide Reductases | 2 | 2007 | 6 | 0.130 |
Why?
|
| Plasmids | 6 | 2007 | 292 | 0.130 |
Why?
|
| Incidence | 6 | 2019 | 1588 | 0.130 |
Why?
|
| Chromatography, Liquid | 3 | 2011 | 105 | 0.130 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2015 | 11 | 0.130 |
Why?
|
| Sarcoma, Ewing | 3 | 2005 | 44 | 0.130 |
Why?
|
| Protein Stability | 2 | 2017 | 101 | 0.130 |
Why?
|
| Machine Learning | 1 | 2017 | 241 | 0.130 |
Why?
|
| Registries | 2 | 2017 | 753 | 0.130 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 24 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2007 | 354 | 0.130 |
Why?
|
| Multivariate Analysis | 5 | 2014 | 994 | 0.130 |
Why?
|
| Methotrexate | 2 | 2007 | 250 | 0.130 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 91 | 0.130 |
Why?
|
| Glypicans | 3 | 2011 | 6 | 0.130 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2015 | 93 | 0.130 |
Why?
|
| Kidney Transplantation | 2 | 2016 | 849 | 0.130 |
Why?
|
| Drug Stability | 1 | 2015 | 48 | 0.130 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2016 | 87 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2016 | 295 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2016 | 81 | 0.130 |
Why?
|
| Pyridazines | 1 | 2015 | 22 | 0.130 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2018 | 437 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 318 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2016 | 113 | 0.130 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2014 | 25 | 0.130 |
Why?
|
| Serine Proteases | 1 | 2014 | 4 | 0.130 |
Why?
|
| Receptors, Androgen | 3 | 2010 | 121 | 0.130 |
Why?
|
| Iron | 1 | 2015 | 166 | 0.130 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2016 | 119 | 0.120 |
Why?
|
| Age Factors | 6 | 2020 | 1857 | 0.120 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 3 | 2003 | 29 | 0.120 |
Why?
|
| Transcriptome | 2 | 2017 | 619 | 0.120 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2014 | 8 | 0.120 |
Why?
|
| Adaptor Protein Complex delta Subunits | 1 | 2014 | 1 | 0.120 |
Why?
|
| Killer Cells, Natural | 2 | 2009 | 273 | 0.120 |
Why?
|
| Adaptor Protein Complex 3 | 1 | 2014 | 2 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2014 | 10 | 0.120 |
Why?
|
| In Situ Hybridization | 3 | 2005 | 312 | 0.120 |
Why?
|
| Liposomes | 1 | 2014 | 93 | 0.120 |
Why?
|
| GATA Transcription Factors | 1 | 2014 | 4 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 307 | 0.120 |
Why?
|
| Bevacizumab | 3 | 2024 | 286 | 0.120 |
Why?
|
| GTP-Binding Proteins | 3 | 2011 | 147 | 0.120 |
Why?
|
| Molecular Epidemiology | 2 | 2011 | 53 | 0.120 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2011 | 42 | 0.120 |
Why?
|
| Receptors, Interleukin-17 | 2 | 2012 | 10 | 0.120 |
Why?
|
| Vaccines, Combined | 1 | 2014 | 5 | 0.120 |
Why?
|
| Allografts | 1 | 2015 | 177 | 0.120 |
Why?
|
| Hepatitis B | 2 | 2012 | 76 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 102 | 0.120 |
Why?
|
| Pleural Neoplasms | 2 | 2008 | 196 | 0.120 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2004 | 37 | 0.120 |
Why?
|
| Smad7 Protein | 1 | 2014 | 7 | 0.120 |
Why?
|
| Graves Disease | 2 | 2011 | 36 | 0.120 |
Why?
|
| Dysostoses | 1 | 2013 | 1 | 0.120 |
Why?
|
| Minisatellite Repeats | 4 | 2012 | 24 | 0.120 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2013 | 12 | 0.120 |
Why?
|
| Receptors, Ghrelin | 2 | 2011 | 4 | 0.120 |
Why?
|
| RNA Stability | 4 | 2007 | 89 | 0.120 |
Why?
|
| Indazoles | 1 | 2014 | 67 | 0.120 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2013 | 21 | 0.120 |
Why?
|
| Adnexa Uteri | 1 | 2013 | 12 | 0.120 |
Why?
|
| Torsades de Pointes | 1 | 2013 | 7 | 0.120 |
Why?
|
| ABO Blood-Group System | 3 | 2021 | 59 | 0.120 |
Why?
|
| Autoantibodies | 3 | 2013 | 268 | 0.120 |
Why?
|
| Sequence Alignment | 4 | 2014 | 353 | 0.120 |
Why?
|
| Ramipril | 1 | 2013 | 2 | 0.120 |
Why?
|
| Angioedema | 1 | 2013 | 4 | 0.120 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 193 | 0.120 |
Why?
|
| Osteoporotic Fractures | 1 | 2014 | 40 | 0.120 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2013 | 35 | 0.120 |
Why?
|
| Telomerase | 2 | 2012 | 60 | 0.120 |
Why?
|
| Hep G2 Cells | 4 | 2018 | 48 | 0.120 |
Why?
|
| Tandem Mass Spectrometry | 5 | 2013 | 104 | 0.110 |
Why?
|
| Neuropeptide Y | 1 | 2013 | 32 | 0.110 |
Why?
|
| Carcinoma, Adenosquamous | 3 | 2014 | 12 | 0.110 |
Why?
|
| Quality of Life | 2 | 2013 | 1646 | 0.110 |
Why?
|
| Tumor Escape | 2 | 2015 | 51 | 0.110 |
Why?
|
| Neprilysin | 1 | 2013 | 41 | 0.110 |
Why?
|
| Bone Neoplasms | 2 | 2009 | 328 | 0.110 |
Why?
|
| Viral Load | 5 | 2011 | 154 | 0.110 |
Why?
|
| Rabbits | 7 | 2010 | 640 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2011 | 59 | 0.110 |
Why?
|
| Lymphotoxin-alpha | 2 | 2004 | 44 | 0.110 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 48 | 0.110 |
Why?
|
| Malaysia | 4 | 2016 | 12 | 0.110 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2004 | 51 | 0.110 |
Why?
|
| Pelvis | 1 | 2013 | 94 | 0.110 |
Why?
|
| Interleukin-6 | 2 | 2014 | 260 | 0.110 |
Why?
|
| Stomach Ulcer | 1 | 2013 | 23 | 0.110 |
Why?
|
| Thorax | 1 | 2013 | 77 | 0.110 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2013 | 63 | 0.110 |
Why?
|
| Receptor, Melanocortin, Type 4 | 2 | 2010 | 4 | 0.110 |
Why?
|
| HTLV-I Infections | 1 | 2013 | 7 | 0.110 |
Why?
|
| Catalogs as Topic | 2 | 2004 | 2 | 0.110 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2013 | 14 | 0.110 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 396 | 0.110 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2013 | 16 | 0.110 |
Why?
|
| Aromatase | 1 | 2013 | 12 | 0.110 |
Why?
|
| Gluconeogenesis | 1 | 2013 | 14 | 0.110 |
Why?
|
| Infant | 5 | 2012 | 3110 | 0.110 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2013 | 9 | 0.110 |
Why?
|
| Sp3 Transcription Factor | 1 | 2013 | 2 | 0.110 |
Why?
|
| Menarche | 1 | 2013 | 28 | 0.110 |
Why?
|
| RNA, Viral | 5 | 2012 | 333 | 0.110 |
Why?
|
| Molecular Conformation | 1 | 2013 | 96 | 0.110 |
Why?
|
| Physical Chromosome Mapping | 1 | 2013 | 27 | 0.110 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2013 | 3 | 0.110 |
Why?
|
| Hydroxylation | 1 | 2013 | 17 | 0.110 |
Why?
|
| Glucose | 2 | 2013 | 630 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 90 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2010 | 122 | 0.110 |
Why?
|
| Histidine | 1 | 2013 | 56 | 0.110 |
Why?
|
| Haptoglobins | 1 | 2012 | 9 | 0.110 |
Why?
|
| Protein Array Analysis | 2 | 2012 | 52 | 0.110 |
Why?
|
| Untranslated Regions | 2 | 2003 | 18 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 24 | 0.110 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2010 | 73 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 588 | 0.110 |
Why?
|
| Methyltransferases | 1 | 2014 | 191 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2017 | 840 | 0.110 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2012 | 12 | 0.110 |
Why?
|
| Cell Membrane | 4 | 2016 | 667 | 0.110 |
Why?
|
| Oligosaccharides | 1 | 2012 | 24 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2017 | 891 | 0.110 |
Why?
|
| Testosterone | 2 | 2012 | 275 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 32 | 0.110 |
Why?
|
| I-kappa B Proteins | 1 | 2012 | 54 | 0.110 |
Why?
|
| Body Height | 2 | 2010 | 100 | 0.110 |
Why?
|
| Hysterectomy | 1 | 2013 | 150 | 0.110 |
Why?
|
| Genes, APC | 2 | 2002 | 26 | 0.110 |
Why?
|
| RNA, Ribosomal | 1 | 2012 | 63 | 0.110 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2012 | 3 | 0.110 |
Why?
|
| Universities | 1 | 2013 | 146 | 0.110 |
Why?
|
| Sarcoma | 2 | 2013 | 220 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2013 | 150 | 0.110 |
Why?
|
| Calpain | 1 | 2013 | 113 | 0.110 |
Why?
|
| DNA Polymerase III | 1 | 2012 | 11 | 0.110 |
Why?
|
| Glycine Dehydrogenase | 1 | 2012 | 1 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2017 | 551 | 0.110 |
Why?
|
| Hypertension | 2 | 2009 | 730 | 0.100 |
Why?
|
| Annexin A4 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2012 | 23 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2012 | 39 | 0.100 |
Why?
|
| Lentivirus | 2 | 2009 | 37 | 0.100 |
Why?
|
| DCC Receptor | 1 | 2012 | 4 | 0.100 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 10 | 0.100 |
Why?
|
| Caspase 3 | 2 | 2010 | 161 | 0.100 |
Why?
|
| Gout | 1 | 2012 | 75 | 0.100 |
Why?
|
| Ankyrins | 1 | 2012 | 23 | 0.100 |
Why?
|
| Bacterial Proteins | 1 | 2018 | 884 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 266 | 0.100 |
Why?
|
| Transaminases | 1 | 2012 | 33 | 0.100 |
Why?
|
| Sensory Receptor Cells | 1 | 2012 | 36 | 0.100 |
Why?
|
| Macular Degeneration | 1 | 2013 | 61 | 0.100 |
Why?
|
| Jurkat Cells | 6 | 2009 | 77 | 0.100 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2012 | 46 | 0.100 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 86 | 0.100 |
Why?
|
| Atherosclerosis | 3 | 2010 | 255 | 0.100 |
Why?
|
| Chemokine CCL22 | 1 | 2011 | 5 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 1231 | 0.100 |
Why?
|
| Drug Hypersensitivity | 2 | 2009 | 37 | 0.100 |
Why?
|
| Microarray Analysis | 4 | 2017 | 96 | 0.100 |
Why?
|
| Megakaryocytes | 1 | 2011 | 36 | 0.100 |
Why?
|
| Zimbabwe | 1 | 2011 | 3 | 0.100 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2011 | 6 | 0.100 |
Why?
|
| Glycine | 1 | 2012 | 94 | 0.100 |
Why?
|
| Epirubicin | 1 | 2011 | 14 | 0.100 |
Why?
|
| Cyclopropanes | 1 | 2011 | 25 | 0.100 |
Why?
|
| Alkynes | 1 | 2011 | 18 | 0.100 |
Why?
|
| HLA-B52 Antigen | 1 | 2011 | 1 | 0.100 |
Why?
|
| Lamivudine | 1 | 2011 | 13 | 0.100 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2010 | 9 | 0.100 |
Why?
|
| Reference Values | 3 | 2012 | 665 | 0.100 |
Why?
|
| Aurora Kinases | 2 | 2012 | 17 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 2 | 2008 | 412 | 0.100 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 2 | 2010 | 42 | 0.100 |
Why?
|
| Aurora Kinase B | 2 | 2012 | 14 | 0.100 |
Why?
|
| Crystallography, X-Ray | 1 | 2013 | 486 | 0.100 |
Why?
|
| China | 4 | 2014 | 230 | 0.100 |
Why?
|
| HLA-C Antigens | 1 | 2011 | 17 | 0.100 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 3 | 2020 | 36 | 0.100 |
Why?
|
| Hydroxymethyl and Formyl Transferases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Microsatellite Repeats | 3 | 2017 | 148 | 0.100 |
Why?
|
| Pedigree | 4 | 2012 | 968 | 0.100 |
Why?
|
| Ghrelin | 1 | 2011 | 29 | 0.100 |
Why?
|
| Enzymes | 1 | 2011 | 47 | 0.100 |
Why?
|
| Sequence Deletion | 1 | 2012 | 205 | 0.100 |
Why?
|
| HLA-DQ Antigens | 1 | 2011 | 51 | 0.100 |
Why?
|
| Wet Macular Degeneration | 1 | 2011 | 25 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2011 | 54 | 0.100 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 1142 | 0.100 |
Why?
|
| Blood Platelets | 1 | 2011 | 150 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 144 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2008 | 112 | 0.100 |
Why?
|
| Cell Extracts | 1 | 2011 | 15 | 0.100 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2011 | 13 | 0.100 |
Why?
|
| Nephrotic Syndrome | 1 | 2011 | 33 | 0.100 |
Why?
|
| Myosin-Light-Chain Phosphatase | 1 | 2010 | 8 | 0.100 |
Why?
|
| Gastric Mucosa | 1 | 2011 | 66 | 0.100 |
Why?
|
| Gene Products, tax | 1 | 2010 | 4 | 0.100 |
Why?
|
| Paroxetine | 1 | 2011 | 26 | 0.100 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2010 | 1 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 36 | 0.100 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 2 | 2013 | 6 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2018 | 1712 | 0.100 |
Why?
|
| Exonucleases | 1 | 2010 | 8 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2011 | 130 | 0.090 |
Why?
|
| Virus Replication | 4 | 2018 | 322 | 0.090 |
Why?
|
| Glioblastoma | 2 | 2004 | 263 | 0.090 |
Why?
|
| Glycomics | 1 | 2010 | 1 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2008 | 42 | 0.090 |
Why?
|
| Calcium | 2 | 2013 | 1170 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2011 | 164 | 0.090 |
Why?
|
| Sirtuins | 1 | 2011 | 46 | 0.090 |
Why?
|
| Gene Knockout Techniques | 3 | 2017 | 79 | 0.090 |
Why?
|
| Wnt Signaling Pathway | 1 | 2011 | 97 | 0.090 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2010 | 41 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2007 | 196 | 0.090 |
Why?
|
| Musculoskeletal System | 1 | 2010 | 15 | 0.090 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2010 | 58 | 0.090 |
Why?
|
| Collagen Type I | 1 | 2011 | 72 | 0.090 |
Why?
|
| Xedar Receptor | 1 | 2010 | 1 | 0.090 | |